Regeneron Acquires 2 Ophthalmological Antibody Programs from Sanofi

Regeneron, a Tarrytown, N.Y.-based biopharmaceuticals company, has announced it has acquired the rights for two ophthalmological antibody programs from its collaborator Sanofi, Chattanooga, Tenn.-based pharmaceutical company.

Advertisement
Carrie Pallardy

The acquired antibody programs, which are in the preclinical process, target platelet derived growth factor and angiopoietin2, respectively.

Regeneron will pay Sanofi $20 million upfront for the two programs and up to $45 million for sales royalties and development milestone payments.

More Articles on Ophthalmology:
Utah Valley Eye Center Joins Effort to Provide Car in Mali
Dr. Rona Silkiss to Perform Cosmetic Oculofacial Plastic Surgery at North Bay ASC
Palmetto Eye & Laser Center Offers Alcon WaveLight Procedures

Real-time pay as a retention tool: Building support, alignment and adoption 

Recommended Live Webinar on Mar 19, 2026 12:00 PM - 1:00 PM CST

Advertisement

Next Up in Ophthalmology

  • Montana physician practice acquired 

    Southlake, Texas-based Retina Consultants of America has acquired Montana Retina Consultants, according to a Feb. 5 news release.  Bozeman-based Montana…

    By: Patsy Newitt

  • Louisiana ophthalmology practice acquired 

    Vision Innovation Partners acquired Ophthalmic Associates of Alexandria (Va.), according to a Feb. 2 press release. Founded in 2010, Ophthalmic…

    By: Patsy Newitt

  • American Board of Ophthalmology names CEO

    The American Board of Ophthalmology has appointed Steven Gedde, MD, as its next CEO.  Dr. Gedde is an ophthalmologist and…

    By: Cameron Cortigiano
Advertisement

Comments are closed.